A paper, made visible
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.
Partial coverage · gaps are marked inside each comparison
- Some results can be visualized; unassessed context remains visible.
Choose a comparison
9 comparisons · Each follows its own evidence.
What happened? statin therapy compared with placebo or usual care
One comparison, followed all the way through
This comparison is not yet interpretable.
Its exact outcome or compared groups still need to be established from the source.
Follow the study
Who or what was studied
patients with and without prior coronary heart disease
What was examined
statin therapy
placebo or usual care
- Comparison-level assignment evidence has not been extracted.
Relative comparison
risk ratio
The reported number can be shown, but its exact outcome or compared groups are unresolved. Its direction cannot be interpreted here.
The confidence interval describes statistical uncertainty under the model, not every possible source of error.
- The outcome name has not been resolved from the source.
- The outcome and group labels are not all tied to this result quotation.
- This quotation reports multiple effects; the semantic roles need review.
Read the source context
Comparison details unresolved.
The exact outcome or compared groups are not yet fully established. The source needs interpretation before this number can support a conclusion.
Read reported excerpt
Statin therapy reduced all-cause mortality, Relative Risk (RR) 0.90 [95% confidence interval (CI) 0.86-0.94, P ≤ 0.0001, I(2)=17%]; cardiovascular disease (CVD) mortality (RR 0.80, 95% CI 0.74-0.87, P<0.0001, I(2)=27%); fatal myocardial infarction (MI) (RR 0.82, 95% CI 0.75-0.91, P<0.0001, I(2)=21%)
Automated source matching has not been reviewed by a scientific expert. This comparison's assignment method is not established.
Keep the limits in view
- An empty limitations list does not mean the study has no limitations.
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Statin therapy reduced all-cause mortality, Relative Risk (RR) 0.90 [95% confidence interval (CI) 0.86-0.94, P ≤ 0.0001, I(2)=17%]; cardiovascular disease (CVD) mortality (RR 0.80, 95% CI 0.74-0.87, P<0.0001, I(2)=27%); fatal myocardial infarction (MI) (RR 0.82, 95% CI 0.75-0.91, P<0.0001, I(2)=21%)
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
AIM: We combined evidence from all RCTs comparing a statin with placebo or usual care among patients with and without prior coronary heart disease (CHD) to determine clinical outcomes.